Catalyze Product Definition Medical Device prototype design/testing and disease target identification and assay development (R61/R33 - Clinical Trial Not Allowed)

The National Institutes of Health (NIH) is seeking applications for the Catalyze Product Definition initiative, which aims to provide early-stage translational support for the development of medical device prototypes, disease target identification, and assay development. The initiative is divided into two phases: the R61 phase, which provides support for initial prototype design and testing, and the R33 phase, which provides support for continued prototype development and testing. The goal of the initiative is to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates. • The initiative is open to various types of applicants, including Native American tribal organizations, nonprofits, and small businesses. • The application deadline is December 23, 2027. • The initiative is expected to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates. • The NIH is seeking applications that propose innovative approaches to medical device prototype design and testing, disease target identification, and assay development.